Driven by the Launch and Uptake of Human Genome Sciences/GlaxoSmithKline’s Benlysta, the Systemic Lupus Erythematosus

In 2020, Benlysta Will Garner Blockbuster Sales in Excess of $1 Billion, According to Findings from Decision Resources

BURLINGTON, Mass.--(BUSINESS WIRE)-- Decision Resources, one of the world’s leading research and advisory firms for pharmaceutical and healthcare issues, finds that, driven primarily by the launch and uptake of Human Genome Sciences/GlaxoSmithKline’s Benlysta, the systemic lupus erythematosus (SLE) drug market will increase more than seven-fold, from approximately $300 million in 2010 to more than $2.1 billion in 2020 in in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

The findings from the Pharmacor topic entitled Systemic Lupus Erythematosus reveal that the premium-priced biologic Benlysta will stand as the market leader in 2020, with blockbuster sales in excess of $1 billion. Benlysta’s position as the first formally approved agent for SLE in more than 50 years, its perceived positive safety profile and its demonstrated efficacy in clinical trials will drive its uptake. The availability of a subcutaneous formulation of Benlysta will also help to bolster its market-leading position in 2020.

“The launch of a subcutaneous formulation of Benlysta, in addition to its currently marketed intravenous formulation, will provide a more convenient delivery option and give this agent an additional competitive edge over other emerging intravenous agents,” said Decision Resources Analyst Dancella Fernandes, Ph.D.

The findings also reveal that, in 2010, the SLE market was largely generic and had significant off-label use. The off-label use of two agents—mycophenolate mofetil (Roche/Galenica’s CellCept, generics) and rituximab (Biogen Idec/Roche/Chugai/Zenyaku Kogyo’s Rituxan, Roche’s MabThera)—generated the majority of market sales in 2010.

The continued uptake of the premium-priced B-cell modulator rituximab will help to drive SLE market growth. Rituximab will achieve sales of nearly $300 million for SLE in 2020 and its uptake will be driven primarily by its use for SLE manifestations that are refractory to current treatments and for patients who are excluded from trials of most other emerging therapies.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group

Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.



CONTACT:

Decision Resources
Christopher Comfort, 781-993-2597
[email protected]

KEYWORDS:   United States  North America  Massachusetts

INDUSTRY KEYWORDS:   Health  Biotechnology  Clinical Trials  Pharmaceutical  General Health

MEDIA:

Suggested Articles

German researchers uncovered 28 antibodies that neutralize COVID-19 and are working with Boehringer Ingelheim to advance them into clinical testing.

Oragenics is ending a phase 2 study of its oral mucositis drug, yanking its IND application and switching its focus to a COVID-19 vaccine.

The vehicle, which Blackstone claims is the largest life sciences private fund, has committed close to $1 billion to companies including Alnylam.